New study shows that targeting an oft-drugged family of cell membrane receptors with biased modulators can expand potential ...

Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...

These preclinical data underscore the potential of ORIC-944 to overcome resistance not only in prostate cancer but in other solid tumors and highlight that the therapeutic potential of PRC2 inhibition ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI ...

Affinity Technologies, Inc. , a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company's noninvasive test for lung cancer, today announced that the Australian ...

Q3 2025 Earnings Call October 29, 2025 4:30 PM EDTCompany ParticipantsChinmay ShuklaNeil Kumar - Co-Founder, CEO ...

The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

A systematic review published today in Psychedelics by Mr. James Gattuso and colleagues at the Florey Institute of Neuroscience and Mental Health synthesizes clinical and preclinical evidence on ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has entered into a partnership with Promega Corporation, a global ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Ozempic, MRI machines and flat screen televisions all emerged out of fundamental research decades earlier — the very types of ...